Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides

Pediatric Pulmonology

Volumn 48, Issue 11, 2013, Pages 1047-1061

  Young, David C ^a,b   Zobell, Jeffery T ^c,d   Stockmann, Chris ^e   Waters, C Dustin ^f   Ampofo, Krow ^e   Sherwin, Catherine M T ^e   Spigarelli, Michael G ^e  

^a UNIVERSITY OF UTAH   (United States)

^b Intermountain Cystic Fibrosis Adult Center   (United States)

^c PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^d Intermountain Cystic Fibrosis Pediatric Center   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f McKay Dee Hospital Center   (United States)

Author keywords

amikacin; aminoglycoside; cystic fibrosis; gentamicin; pharmacodynamics; pharmacokinetics; Pseudomonas aeruginosa; tobramycin

Indexed keywords

AMIKACIN; AZTREONAM; CARBENICILLIN; CEFTAZIDIME; GENTAMICIN; TOBRAMYCIN; TOBRAMYCIN SULFATE;

ANTIBIOTIC RESISTANCE; ARTICLE; CREATININE CLEARANCE; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; HEARING IMPAIRMENT; HUMAN; LUNG FIBROSIS; MICROMONOSPORA; NEPHROTOXICITY; OTOTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; PSEUDOMONAS AERUGINOSA; RISK FACTOR; SIDE EFFECT; STREPTOMYCES; THROMBOCYTOPENIA; TINNITUS; VERTIGO;

AMIKACIN; AMINOGLYCOSIDE; CYSTIC FIBROSIS; GENTAMICIN; PHARMACODYNAMICS; PHARMACOKINETICS; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

ADULT; AMIKACIN; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; GENTAMICINS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 84886430218     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22813     Document Type: Article

References (78)

1. Rowe SM, Miller S, Sorscher EJ,. Cystic fibrosis. N Engl J Med 2005; 352: 1992-2001.
2. Flume PA, Mogayzel PJ Jr., Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC,. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Critic Care Med 2009; 180: 802-808.
3. Zobell JT, Young DC, Waters CD, Ampofo K, Cash J,., Marshall BC, Olson J, Chatfield BA,. A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol 2011; 46: 987-990.
4. Van Meter DJ, Corriveau M, Ahern JW, Lahiri T,. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44: 325-329.
5. Prescott WA Jr., National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther 2011; 16: 262-269.
6. Elphick HE, Tan A,. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2005; CD002007.
7. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ,. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-767.
8. CF Foundation. Microbiology and infectious disease in cystic fibrosis. Cystic Fibrosis Foundation Consensus Conference. 1994.
9. UCF Trust. Antibiotic treatment for cystic fibrosis. UK Cystic Fibrosis Trust Antibiotic Working Group. 2009.
10. Charles FL, Lora LA, Morton PG, Leonard LL,. Drug information handbook. Hudson OH: Lexi-Comp, Inc. 2011.
11. Zobell JT, Young DC, Waters CD, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. Aztreonam and carbapenems. Pediatr Pulmonol 2012; 47: 1147-1158.
12. Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins. Pediatr Pulmonol 2013; 48: 107-122.
13. Stockmann C, Sherwin CM, Zobell JT, Young DC, Waters CD, Spigarelli MG, Ampofo, K,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. Fluoroquinolones. Pediatr Pulmonol 2013; 48: 211-220.
14. Young DC, Zobell JT, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. Colistimethate sodium. Pediatr Pulmonol 2013; 48: 1-7.
15. Tobramycin inhalation solution. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 2009.
16. Stephens D, Garey N, Isles A, Levison H, Gold R,. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis 1983; 2: 209-211.
17. Cooper DM, Harris M, Mitchell I,. Comparison of intravenous and inhalation antibiotic therapy in acute pulmonary deterioration in cystic fibrosis. Am Rev Respir Dis 1985; 131: A242.
18. Ryan G, Jahnke N, Remmington T,. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev 2012; 12: CD008319.
19. Schaad UB, Wedgwood-Krucko J, Suter S, Kraemer R,. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987; 111: 599-605.
20. Chambers HF,. Antimicrobial agents: the aminoglycosides. In:, JGHALE, Limbird, editor. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. pp 1219-1238.
21. Amikacin sulfate approved package labeling. Bedford, OH: Bedford Laboratories. 2007.
22. Gentamicin sulfate approved package labeling. Irvine, CA: Braun Medical, Inc. 2007.
23. Tobramycin sulfate approved package labeling. 2008. Schaumburg, IL: APP Pharmaceuticals, LLC.
24. Edson RS, Terrell CL,. The aminoglycosides. Mayo Clin Proc 1999; 74: 519-528
25. Burgess DS,. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005; 40: S99-S104.
26. Moore RD, Lietman PS, Smith CR,. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to MIC. J Infect Dis 1987; 155: 93-99.
27. Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T,. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development ? J Antimicrob Chemother 2006; 58: 822-829.
28. Mouton JW, Jacobs N, Tiddens H, Horrevorts AM,. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis 2005; 52: 123-127.
29. Autret E, Marchand S, Breteau M, Grenier B,. Pharmacokinetics of amikacin in cystic fibrosis: a study of bronchial diffusion. Eur J Clin Pharmacol 1986; 31: 79-83.
30. Grenier B, Autret E, Marchand S, Thompson R,. Kinetic parameters of amikacin in cystic fibrosis children. Infection 1987; 15: 295-299.
31. Vic P, Ategbo S, Turck D, Husson MO, Tassin E, Loeuille GA, Deschildre A, Druon D, Elian JC, Arrouet-Lagandre C,. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Eur J Pediatr 1996; 155: 948-953.
32. Canis F, Husson MO, Turck DM, Vic P, Launay V, Ategbo S, Vincent A, Courcol RJ,. Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients. J Antimicrob Chemother 1997; 39: 431-433.
33. Beringer PM, Vinks AA, Jelliffe RW,. Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. J Antimicrob Chemother 1998; 41: 142-144.
34. Byl B, Baran D, Jacobs F, Herschuelz A, Thys JP,. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. J Antimicrob Chemother 2001; 48: 325-327.
35. Kearns GL, Hilman BC, Wilson JT,. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr 1982; 100: 312-318.
36. Mann HJ, Canafax DM, Cipolle RJ, Daniels CE, Zaske DE, Warwick WJ,. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol 1985; 1: 238-243.
37. Bauer LA, Piecoro JJ, Jr., Wilson HD, Blouin RA,. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis. Clin Pharm 1983; 2: 262-264.
38. Hendeles L, Iafrate RP, Stillwell PC, Mangos JA,. Individualizing gentamicin dosage in patients with cystic fibrosis: limitations to pharmacokinetic approach. J Pediatr 1987; 110: 303-310.
39. MacDonald NE, Anas NG, Peterson RG, Schwartz RH, Brooks JG, Powell KR,. Renal clearance of gentamicin in cystic fibrosis. J Pediatr 1983; 103: 985-990.
40. Campbell D, Thomson AH, Stack B,. Population pharmacokinetics of aminoglycoside antibiotics in patients with cystic fibrosis. Ther Drug Monit 1999; 21: 281-288.
41. de Groot R, Smith AL,. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet 1987; 13: 228-253.
42. Rey E, Treluyer JM, Pons G,. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35: 313-329.
43. Levy J, et al. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984; 105: 117-124.
44. Lindsay CA, Bosso JA,. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations. Clin Pharmacokinet 1993; 24: 496-506.
45. Prandota J,. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 1988; 35: 542-578.
46. Hsu MC, Aguila HA, Schmidt VL, Munzenberger PJ, Kauffman RE, Polgar G,. Individualization of tobramycin dosage in patients with cystic fibrosis. Pediatr Infect Dis 1984; 3: 526-529.
47. Kelly HB, Menendez R, Fan L, Murphy S,. Pharmacokinetics of tobramycin in cystic fibrosis. J Pediatr 1982; 100: 318-321.
48. Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ,. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother 2002; 50: 553-559.
49. Bates RD, Nahata MC, Jones JW, McCoy K, Young G, Cox S, Barson WJ,. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 1997; 112: 1208-1213.
50. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ,. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother 2000; 44: 809-813.
51. Bragonier R, Brown NM,. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. J Antimicrob Chemother 1998; 42: 103-106.
52. Guglielmo BJ, Quan LA, Stulbarg MS,. Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients. J Antimicrob Chemother 1996; 37: 1040-1042.
53. Massie J, Cranswick N,. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. J Paediatr Child Health 2006; 42: 601-605.
54. Munzenberger PJ, Commissaris RL, Massoud N, Hsu MC,. Variability of tobramycin pharmacokinetics in cystic fibrosis. Pediatr Infect Dis J 1987; 6: 739-743.
55. Roberts GW, Nation RL, Jarvinen AO, Martin AJ,. An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients. Br J Clin Pharmacol 1993; 36: 372-375.
56. Touw DJ, Vinks AA, Neef C,. Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm. Pharm World Sci 1997; 19: 142-151.
57. Touw DJ, Knox AJ, Smyth A,. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibrosis 2007; 6: 327-333.
58. Vic P, Ategbo, S,., Turck D, Husson MO, Launay V, Loeuille GA, Sardet A, Deschildre A, Druon D, Arrouet-Lagande C,. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 1998; 78: 536-539.
59. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S,. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 2002; 19: 303-309.
60. Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, Onishko CR, Martin AJ, Linke RJ, Holmes M,. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatr Pulmonol 2001; 31: 367-376.
61. Hennig S, Norris R, Kirkpatrick CM,. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis-a population pharmacokinetic study. Br J Clin Pharmacol 2008; 65: 502-510.
62. Lau WK, Young LS, Osher AB, Dooley RR,. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Pediatrics 1977; 60: 372-377.
63. Schaad UB, Wedgwood-Krucko J, Guenin K, Buehlmann U, Kraemer R,. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 1989; 8: 858-865.
64. Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, Denning CR,. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J Pediatr 1977; 90: 144-148.
65. Penketh AR, Hodson ME, Batten JC,. Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis. Br J Dis Chest 1983; 77: 179-184.
66. Martin AJ, Smalley CA, George RH, Healing DE, Anderson CM,. Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis. Arch Dis Child 1980; 55: 604-607.
67. Drew J, Watson AR, Smyth A,. Acute renal failure and cystic fibrosis. Arch Dis Child 2003; 88: 646.
68. Bertenshaw C, Watson AR, Lewis S, Smyth A,. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2007; 62: 541-545.
69. Smyth A, Lewis, S, Bertenshaw C, Choonara I, McGaw J, Watson A,. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008; 63: 532-535.
70. Schumock GT, Raber SR, Crawford SY, Naderer OJ, Rodvold KA,. National survey of once-daily dosing of aminoglycoside antibiotics. Pharmacotherapy 1995; 15: 201-209.
71. Tan KH, Hyman-Tylor P, Mulheran M, Knox A, Smyth A,. Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers. Pediatr Pulmonol 2002; 33: 165.
72. Phillips JA, Bell SC,. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia. Intern Med J 2001; 31: 23-36.
73. Smyth AR, Tan KH,. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2006; 3: CD002009.
74. Smyth AR, Bhatt J,. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev CD002009.
75. Barza M, Loannidis JP, Cappelleri JC, Lau J,. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312: 338-345.
76. Riethmueller J, Ballmann M, Schroeter TW, Franke P, von Butler, R, Claass A, Junge S, Doering G, Stern M, German Multicenter Study, Group. Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection 2009; 37: 424-431.
77. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A,. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005; 365: 573-578.
78. Wood PJ, Loannides-Demos LL, Li SC, Williams TJ, Hickey B, Spicer WJ, Hooper RE, McLean AJ,. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996; 51: 369-373.